NPPB and chronic kidney disease: A 2023 clinical study reaffirmed markedly high BNP concentrations in CKD patients and suggested its application as a cardiovascular prognostic marker.22 In contrast, Takahama et al. presented a conflicting report that mentioned NT-proBNP levels were raised in CKD even without apparent cardiac pathology but mostly due to impaired renal clearance.21 In the present study, BNP was more effective than NT-proBNP in detecting cardiovascular stress and hence is a better biomarker for this CKD group.